

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number  
**WO 2004/029026 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 213/82**,  
401/12, A61K 31/44, 31/444, 31/4439, A61P 29/00, C07D  
407/12, 409/12

(21) International Application Number:  
PCT/EP2003/010930

(22) International Filing Date:  
25 September 2003 (25.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0222493.9 27 September 2002 (27.09.2002) GB

(71) Applicant (for all designated States except US): **GLAXO  
GROUP LIMITED** [GB/GB]; Glaxo Wellcome House,  
Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventor: **GREEN, Richard, Howard** (deceased).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EATHERTON,**  
**Andrew, John** [GB/GB]; GlaxoSmithKline, The Fry-  
the, Welwyn, Hertfordshire AL6 9AR (GB). **GIBLIN,**  
**Gerard, Martin, Paul** [GB/GB]; GlaxoSmithKline,  
The Frythe, Welwyn, Hertfordshire AL6 9AR (GB).  
**JANDU, Karamjit, Singh** [GB/GB]; GlaxoSmithKline,  
The Frythe, Welwyn, Hertfordshire AL6 9AR (GB).  
**MITCHELL, William, Leonard** [GB/GB]; Glaxo-  
SmithKline, The Frythe, Welwyn, Hertfordshire AL6  
9AR (GB). **NAYLOR, Alan** [GB/GB]; GlaxoSmithKline,  
Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY  
(GB). **PALOMBI, Giovanni** [IT/IT]; NiKem Research  
S.r.L., Via Zambelletti, 25, Baranzate di Bollate, I-20021

Milan (IT). **RAWLINGS, Derek, Anthony** [GB/GB];  
GlaxoSmithKline, The Frythe, Welwyn, Hertfordshire  
AL6 9AR (GB). **SLINGSBY, Brian, Peter** [GB/GB];  
GlaxoSmithKline, The Frythe, Welwyn, Hertfordshire  
AL6 9AR (GB). **WHITTINGTON, Andrew, Richard**  
[GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Steve-  
nage, Hertfordshire SG1 2NY (GB).

(74) Agent: **HOCKLEY, Slan, Catherine**; GlaxoSmithKline,  
CIP (CN925.1), 980 Great West Road, Brentford, Middle-  
sex TW8 9GS (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS

(57) Abstract: The present invention relates to novel pyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

WO 2004/029026 A1